Chronic Lung Allograft Dysfunction MRI Study

NCT ID: NCT06406777

Last Updated: 2025-03-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-20

Study Completion Date

2028-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This studies purpose is to confirm the efficacy and efficiency of using OE-MRI and MRI with hyperpolarized gas techniques and Iodinated contrast CT scan, this will enhance understanding of CLAD pathophysiology. Moreover, this project is foundational to performing additional studies to establish if novel MRI imaging can serve as an objective confirmatory diagnostic tool for CLAD in post-transplant patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This studies purpose is to confirm the efficacy and efficiency of using OE-MRI and MRI with hyperpolarized gas techniques and Iodinated contrast CT scan, this will enhance understanding of CLAD pathophysiology. Moreover, this project is foundational to performing additional studies to establish if novel MRI imaging can serve as an objective confirmatory diagnostic tool for CLAD in post-transplant patients.

This observational imaging study will use 3T UTE MRI with varying oxygen levels (room air vs. 100% oxygen) to evaluate lung ventilation using oxygen enhanced imaging, in 50 healthy normal subjects (age 18-80).

Subjects will have vital signs taken, complete questionnaires and have pulmonary function test (spirometry) done, Iodinated contrast CT scan and standard of care CT scans, in addition to one MRI session that will include 6 series of scans. The MRI scans will be taken in supine position (laying on back) and include breathing room air and 100% oxygen. OE-MRI will be done in addition to MRI scans with Xenon-129.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Lung Allograft Dysfunction Lung MRI (CLAD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Three populations that will all have the same interventions.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Normal Subjects

Healthy subjects, with no lung diagnosis, who are non-smokers.

Group Type ACTIVE_COMPARATOR

Spirometry

Intervention Type DIAGNOSTIC_TEST

Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.

Contrast Lung Computed Tomography (CT) Scan

Intervention Type DIAGNOSTIC_TEST

CT scan of the lungs using contrast

Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan

Intervention Type DIAGNOSTIC_TEST

MRI will be taken while subject is lying on their back breathing 100% oxygen.

129Xe MRI scans

Intervention Type DRUG

MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.

Post Lung Transplant with normal functioning

Subjects who have had a lung transplant and now have normal lung function

Group Type EXPERIMENTAL

Spirometry

Intervention Type DIAGNOSTIC_TEST

Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.

Contrast Lung Computed Tomography (CT) Scan

Intervention Type DIAGNOSTIC_TEST

CT scan of the lungs using contrast

Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan

Intervention Type DIAGNOSTIC_TEST

MRI will be taken while subject is lying on their back breathing 100% oxygen.

129Xe MRI scans

Intervention Type DRUG

MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.

Post Lung Transplant with Chronic Lung Allograft Dysfunction (CLAD)

Subjects who have had a lung transplant that now have CLAD

Group Type EXPERIMENTAL

Spirometry

Intervention Type DIAGNOSTIC_TEST

Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.

Contrast Lung Computed Tomography (CT) Scan

Intervention Type DIAGNOSTIC_TEST

CT scan of the lungs using contrast

Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan

Intervention Type DIAGNOSTIC_TEST

MRI will be taken while subject is lying on their back breathing 100% oxygen.

129Xe MRI scans

Intervention Type DRUG

MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spirometry

Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.

Intervention Type DIAGNOSTIC_TEST

Contrast Lung Computed Tomography (CT) Scan

CT scan of the lungs using contrast

Intervention Type DIAGNOSTIC_TEST

Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan

MRI will be taken while subject is lying on their back breathing 100% oxygen.

Intervention Type DIAGNOSTIC_TEST

129Xe MRI scans

MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 18-80
* English Speaking Subjects
* Willingness and ability to provide informed consent
* Non-smoker


* \>/= 6 months from lung transplant
* History of bilateral lung transplant


* Stable spirometry with FEV1 \> 90% of baseline value (average of 2 best values) and forced mid-expiratory flow (FEF) (25-75) \> 75% of baseline
* Total Lung Capacity (TLC) \> 90 % of baseline
* Post-transplant chest radiograph without significant abnormality
* No evidence of on-going lung infection or allograft rejection


* FEV1 \< 80% of baseline value (average of 2 best values)
* Follow up 6-months or decline in lung function (20% decrease in FEV1 without evidence of infection or acute rejection)

Exclusion Criteria

* SAO2 drops below 90% (in absence of mechanical failure) during normal tidal breathing
* Unilateral diaphragm paralysis
* Evidence of acute illness on day of study
* Evidence of restrictive lung disease
* Dependence on supplemental oxygen
* History of cardiac disease
* Pregnancy (self-declared)
* Lactating women
* Participants with metal objects in their body
* Known contraindication to MRI examination
* Systolic blood pressure reading of \< 100 mmHg or \> 200 mmHg
* Diastolic blood pressure reading of \<60 mmHg or \> 100 mmHg
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sean Fain

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sean Fain

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sean Fain, Ph.D

Role: PRINCIPAL_INVESTIGATOR

University of Iowa

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Iowa

Iowa City, Iowa, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sean Fain, Ph.D.

Role: CONTACT

319 356 4832

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sean Fail, PhD

Role: primary

319-356-4832

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202304226

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis
NCT04071769 ACTIVE_NOT_RECRUITING PHASE2
129 Xenon MRI in Chronic Lung Disease
NCT02723500 RECRUITING NA
Functional Applications of Hyperpolarized 129Xe MRI
NCT01697332 TERMINATED PHASE1/PHASE2
Imaging Regional Lung Defect Severity
NCT01640288 COMPLETED PHASE1/PHASE2
Upright MRI in Lung Disease
NCT03531775 UNKNOWN NA
Xenon MRI and Progressive ILD
NCT05241275 ACTIVE_NOT_RECRUITING PHASE2